Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The study pop. was defined by the inclusion criteria. This study was carried out in 14 centers in Brazil with inclusion 2 months after the first study subject, started in Aug 06. After the screening visit, the patients that met inclusion and exclusion criteria were selected to participate in the study. The last patient out was in Jul 07.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A wash out period was needed in case of a previous inefficient antihypertensive medication, so it was interrupted from 2 to 3 wks before the enrollment. The patient could be excluded considering the exclusion criteria.

Reporting Groups

Description

Olmesartan + Hydrochlorothiazide + Amlodipine

olmesartan monotherapy was the starting dosage regimen. Blood pressure (BP) measurments were obtained at 4, 8 and 9 weeks. If BP goals were not met at a measurment point the participant's medication was elevated to the next step and BP measurments taken at the next 4, 8, and 9 weeks. olmesartan 20 mg/ hydrochlorothiazide 12.5 mg tablets was the first titration regimen if blood pressure goals were not achieved olmesartan 40 mg + hydrochlorothiazide 25 mg tablets was the second titration regimen if blood pressure goals were not achieved olmesartan 40 mg + hydrochlorothiazide 25 mg tablets + amlodipine 5 mg tablets was the third titration regimen if blood pressure goals were not achieved

Participant Flow:   Overall Study

	Olmesartan + Hydrochlorothiazide + Amlodipine
STARTED	144
COMPLETED	124
NOT COMPLETED	20
Lack of Efficacy	20

Reporting Groups

Description

Olmesartan + Hydrochlorothiazide + Amlodipine

olmesartan monotherapy was the starting dosage regimen. Blood pressure (BP) measurments were obtained at 4, 8 and 9 weeks. If BP goals were not met at a measurment point the participant's medication was elevated to the next step and BP measurments taken at the next 4, 8, and 9 weeks. olmesartan 20 mg/ hydrochlorothiazide 12.5 mg tablets was the first titration regimen if blood pressure goals were not achieved olmesartan 40 mg + hydrochlorothiazide 25 mg tablets was the second titration regimen if blood pressure goals were not achieved olmesartan 40 mg + hydrochlorothiazide 25 mg tablets + amlodipine 5 mg tablets was the third titration regimen if blood pressure goals were not achieved

Baseline Measures

	Olmesartan + Hydrochlorothiazide + Amlodipine
Number of Participants   [units: participants]	144
Age   [units: participants]
<=18 years	0
Between 18 and 65 years	132
>=65 years	12
Gender   [units: participants]
Female	74
Male	70
Race/Ethnicity, Customized   [units: Participants]
Black	24
White	83
Asian	7
Other	30
Region of Enrollment   [units: participants]
Brazil	144

1.  Primary:

Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 (Olmesartan 20 mg Monotherapy)   [ Time Frame: 4 - 9 wks of olmesartan monotherapy ]

2.  Primary:

Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in First Titrated Group (Olmesartan 20 mg + 12.5 mg Hydrochlorothiazide)   [ Time Frame: 4 to 9 weeks on combination therapy ]

3.  Primary:

Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in Second Titrated Group (Olmesartan 40 mg + 25 mg Hydrochlorothiazide)   [ Time Frame: 4 to 9 weeks ]

4.  Primary:

Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in Third Titrated Group (Olmesartan + Hydrochorothiazide + Amlodipine)   [ Time Frame: 4 - 9 weeks ]